Cargando…

Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease

Fibroblast growth factor 21 (FGF21) is an endocrine factor that regulates glucose and lipid metabolism. Circulating FGF21 predicts cardiovascular events and mortality in type 2 diabetes mellitus, including early-stage chronic kidney disease, but its impact on clinical outcomes in end-stage renal dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohara, Marina, Masuda, Takahiro, Shiizaki, Kazuhiro, Akimoto, Tetsu, Watanabe, Yuko, Honma, Sumiko, Sekiguchi, Chuji, Miyazawa, Yasuharu, Kusano, Eiji, Kanda, Yoshinobu, Asano, Yasushi, Kuro-o, Makoto, Nagata, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459464/
https://www.ncbi.nlm.nih.gov/pubmed/28582462
http://dx.doi.org/10.1371/journal.pone.0178971
_version_ 1783241971679100928
author Kohara, Marina
Masuda, Takahiro
Shiizaki, Kazuhiro
Akimoto, Tetsu
Watanabe, Yuko
Honma, Sumiko
Sekiguchi, Chuji
Miyazawa, Yasuharu
Kusano, Eiji
Kanda, Yoshinobu
Asano, Yasushi
Kuro-o, Makoto
Nagata, Daisuke
author_facet Kohara, Marina
Masuda, Takahiro
Shiizaki, Kazuhiro
Akimoto, Tetsu
Watanabe, Yuko
Honma, Sumiko
Sekiguchi, Chuji
Miyazawa, Yasuharu
Kusano, Eiji
Kanda, Yoshinobu
Asano, Yasushi
Kuro-o, Makoto
Nagata, Daisuke
author_sort Kohara, Marina
collection PubMed
description Fibroblast growth factor 21 (FGF21) is an endocrine factor that regulates glucose and lipid metabolism. Circulating FGF21 predicts cardiovascular events and mortality in type 2 diabetes mellitus, including early-stage chronic kidney disease, but its impact on clinical outcomes in end-stage renal disease (ESRD) patients remains unclear. This study enrolled 90 ESRD patients receiving chronic hemodialysis who were categorized into low- and high-FGF21 groups by the median value. We investigated the association between circulating FGF21 levels and the cardiovascular event and mortality during a median follow-up period of 64 months. A Kaplan-Meier analysis showed that the mortality rate was significantly higher in the high-FGF21 group than in the low-FGF21 group (28.3% vs. 9.1%, log-rank, P = 0.034), while the rate of cardiovascular events did not significantly differ between the two groups (30.4% vs. 22.7%, log-rank, P = 0.312). In multivariable Cox models adjusted a high FGF21 level was an independent predictor of all-cause mortality (hazard ratio: 3.98; 95% confidence interval: 1.39–14.27, P = 0.009). Higher circulating FGF21 levels were associated with a high mortality rate, but not cardiovascular events in patient with ESRD, suggesting that circulating FGF21 levels serve as a predictive marker for mortality in these subjects.
format Online
Article
Text
id pubmed-5459464
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-54594642017-06-15 Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease Kohara, Marina Masuda, Takahiro Shiizaki, Kazuhiro Akimoto, Tetsu Watanabe, Yuko Honma, Sumiko Sekiguchi, Chuji Miyazawa, Yasuharu Kusano, Eiji Kanda, Yoshinobu Asano, Yasushi Kuro-o, Makoto Nagata, Daisuke PLoS One Research Article Fibroblast growth factor 21 (FGF21) is an endocrine factor that regulates glucose and lipid metabolism. Circulating FGF21 predicts cardiovascular events and mortality in type 2 diabetes mellitus, including early-stage chronic kidney disease, but its impact on clinical outcomes in end-stage renal disease (ESRD) patients remains unclear. This study enrolled 90 ESRD patients receiving chronic hemodialysis who were categorized into low- and high-FGF21 groups by the median value. We investigated the association between circulating FGF21 levels and the cardiovascular event and mortality during a median follow-up period of 64 months. A Kaplan-Meier analysis showed that the mortality rate was significantly higher in the high-FGF21 group than in the low-FGF21 group (28.3% vs. 9.1%, log-rank, P = 0.034), while the rate of cardiovascular events did not significantly differ between the two groups (30.4% vs. 22.7%, log-rank, P = 0.312). In multivariable Cox models adjusted a high FGF21 level was an independent predictor of all-cause mortality (hazard ratio: 3.98; 95% confidence interval: 1.39–14.27, P = 0.009). Higher circulating FGF21 levels were associated with a high mortality rate, but not cardiovascular events in patient with ESRD, suggesting that circulating FGF21 levels serve as a predictive marker for mortality in these subjects. Public Library of Science 2017-06-05 /pmc/articles/PMC5459464/ /pubmed/28582462 http://dx.doi.org/10.1371/journal.pone.0178971 Text en © 2017 Kohara et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kohara, Marina
Masuda, Takahiro
Shiizaki, Kazuhiro
Akimoto, Tetsu
Watanabe, Yuko
Honma, Sumiko
Sekiguchi, Chuji
Miyazawa, Yasuharu
Kusano, Eiji
Kanda, Yoshinobu
Asano, Yasushi
Kuro-o, Makoto
Nagata, Daisuke
Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease
title Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease
title_full Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease
title_fullStr Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease
title_full_unstemmed Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease
title_short Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease
title_sort association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459464/
https://www.ncbi.nlm.nih.gov/pubmed/28582462
http://dx.doi.org/10.1371/journal.pone.0178971
work_keys_str_mv AT koharamarina associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease
AT masudatakahiro associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease
AT shiizakikazuhiro associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease
AT akimototetsu associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease
AT watanabeyuko associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease
AT honmasumiko associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease
AT sekiguchichuji associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease
AT miyazawayasuharu associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease
AT kusanoeiji associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease
AT kandayoshinobu associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease
AT asanoyasushi associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease
AT kuroomakoto associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease
AT nagatadaisuke associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease